Published in Vaccine Weekly, October 26th, 2005
Mologen successfully scaled up its production process following GMP (Good Manufacturing Practice) guidelines and finished the extension process for the Berlin production sites, which had been started in 2004.
The agents, which are produced in compliance with GMP standards, are permitted to be used in and sold for clinical studies in the future.
The increased production capacities are able to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly